A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension

Cardiovascular Diseases Clinical Trial

— DAN-PTRA  

Official title:

A Prospective Danish National Registry of Percutaneous Transluminal Renal Angioplasty in Patients With Renovascular Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02770066
• Other study ID #: DAN-PTRA
• Status: Recruiting
• Start date: January 2015
• Est. completion date: January 2030

Study information

• Verified date: May 2024
• Source: University of Aarhus
• Contact: Mark Reinhard, PhD
• Phone: +45 7845 2455
• Email: m.reinhard[@]dadlnet.dk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A prospective Danish national registry of percutaneous transluminal renal angioplasty (PTRA) in high-risk patients with renal artery stenosis selected on the basis of common national criteria, and with a common follow-up protocol for all three Danish centres offering PTRA

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2030
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Eligibility criteria

1. True resistant hypertension (= 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) and uncontrolled blood pressure confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is = 130 mmHg the patient can be evaluated for renal artery stenosis.

2. Hypertension and intolerance or side effects of the antihypertensive treatment. Hypertension is confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is = 130 mmHg the patient can be evaluated for renal artery stenosis.

3. Progressive renal insufficiency (a reduction in eGFR > 5 ml/min/1,73 m2 per year) in patients with bilateral renal artery stenosis or in patients with renal artery stenosis and only one kidney.

4. Recurrent heart failure/pulmonary edema and resistant hypertension (= 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) that may not be attributed to non-compliance, reduced left heart ventricular ejection fraction/heart valve disease or other obvious explanations (atrial fibrillation, fever, hyperthyroidism etc.). If the average 24-hour ambulatory systolic blood pressure is = 130 mmHg after nurse-administered medication the patient can be evaluated for renal artery stenosis.

5. Younger patients (< 40 years) with hypertension (24-hour ambulatory blood pressure monitoring = 130/80 mmHg after nurse-administered medication )

Inclusion Criteria:

All of the following:

1. At least one of the above eligibility criteria

2. Duplex doppler ultrasonography or renography investigations consistent with hemodynamically significant renal artery stenosis

3. CT angiography or renal arteriography with angiographic renal artery stenosis of = 70 % reduction of the luminal diameter in at least one projection

Exclusion Criteria:

1. If angiography/arteriography, ultrasonography or renography is consistent with bilateral significant renal artery stenosis and only one side is treated with PTRA

2. PTRA of a renal artery supplying a kidney which pre-PTRA handles = 10% of the total kidney function (with no blockage of the renin-angiotensin system) and has a kidney size < 7 cm (length)

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Hypertension
• Hypertension, Renovascular
• Kidney Diseases
• Renal Artery Obstruction

Intervention

Device:
• Percutaneous transluminal renal angioplasty
Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia) Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician Antiplatelet therapy (usually standard) Cholesterol-lowering drugs (usually standard) Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated) Smoking cessation, diet and physical activity (usually standard)

Locations

Country	Name	City	State
Denmark	Aalborg University Hospital	Aalborg
Denmark	Aarhus University Hospital	Aarhus N
Denmark	Glostrup University Hospital/ Rigshospitalet	Glostrup
Denmark	Holbaek Hospital	Holbaek
Denmark	Odense University Hospital	Odense C

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in 24-hour ambulatory systolic and diastolic blood pressures from baseline to 24 months after PTRA in patients with 24-hour ambulatory average systolic blood pressure = 150 mmHg at baseline	Changes in 24-hour ambulatory systolic and diastolic blood pressures (calculated from hourly means) from baseline to 24 months after percutaneous transluminal renal angioplasty in patients with 24-hour ambulatory average systolic blood pressure = 150 mmHg at baseline and with significant artery stenosis either; Unilaterally (one or two kidneys); Bilaterally with treatment of both kidneys; All 24-hour ambulatory blood pressure measurements are performed after nurse-administered medication. Likewise, it will below be inferred that renal artery stenosis is defined as in the primary endpoint.	Measured 24 months post-PTRA
Secondary	Changes in 24-hour ambulatory systolic and diastolic blood pressures from baseline to 24 months after PTRA in patients with 24-hour ambulatory average systolic blood pressure = 130 mmHg at baseline	Changes in 24-hour ambulatory systolic and diastolic blood pressures (calculated from hourly means) from baseline to 24 months after percutaneous transluminal renal angioplasty in patients with 24-hour ambulatory average systolic blood pressure = 130 mmHg at baseline and with significant artery stenosis	Measured 24 months post-PTRA
Secondary	Changes in 24-hour ambulatory systolic and diastolic blood pressures (statistically adjusted for treatment changes) from baseline to 24 months after PTRA in patients with 24-hour ambulatory average systolic blood pressure = 150 mmHg at baseline	Changes in 24-hour ambulatory systolic and diastolic blood pressures (calculated from hourly means) (statistically adjusted for treatment changes) from baseline to 24 months after percutaneous transluminal renal angioplasty in patients with 24-hour ambulatory average systolic blood pressure = 150 mmHg at baseline and with significant artery stenosis	Measured 24 months post-PTRA
Secondary	Changes in 24-hour ambulatory systolic and diastolic blood pressures (statistically adjusted for treatment changes) from baseline to 24 months after PTRA in patients with 24-hour ambulatory average systolic blood pressure = 130 mmHg at baseline	Changes in 24-hour ambulatory systolic and diastolic blood pressures (calculated from hourly means) (statistically adjusted for treatment changes) from baseline to 24 months after percutaneous transluminal renal angioplasty in patients with 24-hour ambulatory average systolic blood pressure = 130 mmHg at baseline and with significant artery stenosis	Measured 24 months post-PTRA
Secondary	Changes in 24-hour ambulatory systolic and diastolic blood pressures (unadjusted and statistically adjusted for treatment changes)	Changes in 24-hour ambulatory systolic and diastolic blood pressures (unadjusted and statistically adjusted for treatment changes) from baseline to 3, 12, 36, 48 and 60 months after PTRA in patients with 24-hour ambulatory average systolic blood pressure = 150 mmHg and in patients with 24-hour ambulatory average systolic blood pressure = 130 mmHg	Measured at 3, 12, 36, 48 and 60 months
Secondary	Change in antihypertensive treatment (defined daily doses)		Measured at 3, 12, 24, 36, 48 and 60 months
Secondary	Change in kidney function	Change in estimated glomerular filtration rate (eGFR) and change in percentage side distribution measured by renography at baseline and 24 months after PTRA	Measured at 3, 12, 24, 36, 48 and 60 months
Secondary	Clinical composite end point	Clinical composite end point; death from cardiovascular causes; death from renal causes; stroke; myocardial infarction; hospitalization for congestive heart failure; progressive renal insufficiency (a reduction from baseline of 30% or more in eGFR); permanent renal-replacement therapy; Only the first event per participant is included in the composite	Measured at 3, 12, 24, 36, 48 and 60 months
Secondary	Safety composite end point (< 30 days after PTRA)	Safety composite end point (< 30 days after PTRA); all cause mortality; rupture, dissection, perforation or occlusion of renal artery; critical bleeding (need of blood transfusion); embolization; significant loss of kidney function (reduction from baseline of 30% or more in eGFR); ipsilateral nephrectomy; pseudoaneurysm formation; stent thrombosis; Only the first event per participant is included in the composite	Measured at 3, 12, 24, 36, 48 and 60 months